Global Phase III programme for D-Pharm's neurorotective extended to S Korea
This article was originally published in Scrip
D-Pharm's local licensee Yungjin Pharmaceutical has received approval from South Korea's FDA to begin a Phase III trial in the country with D-Pharm's neuroprotective and lead product candidate DP-b99.
You may also be interested in...
Japanese ophthalmic specialist picks up young private US firm and gains a small but broad set of marketed products.
Cancer deals involving Junshi/Wigen, Allist/Octimet, Yufan/Abound, Takeda/Presage, Daiichi Sankyo/AnHeart, LegoChem/Harbour Biomed, plus a stem cell partnership and a lysosomal storage disorder agreement.
Japan coordinates initiative to improve regional early-stage development of novel cancer therapies, which will work both with the industry and independently to improve access.